European Headache Alliance

Monthly Archives: November 2018

“Green light” to Lilly’s monoclonal antibody to migraine

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes…
Read More

Migraine Atlas by AEMICE

AEMICE together with Universidad de Sevilla (Seville University) and Novartis and a scientific committee of expert neurologists has created the "Migraine Atlas 2018" which reflects the real situation of the 4.5 million people who suffer from migraine in Spain! Unlike other studies "Migraine Atlas" includes the patients and also their families perspective about their condition, the healthcare system,…
Read More

Congratulations Kalina!!

We would like to give the warmest and biggest congratulations to our Board Officer and Cluster Headache Delegate, Kalina Tyminski!!! We are beyond proud to announce that Mrs. Tyminski just received a Certificate of Commendation for Young Volunteer Advocate from the EFNA Advocacy Awards 2018.  Thank you for all your hard work, dedication, outstanding contribution…
Read More